miriplatin

{{Short description|Chemical compound}}

{{Infobox drug

| drug_name = Miriplatin

| INN =

| type =

| image = Miriplatin.svg

| image2 = Miriplatin 3D BS.png

| pronounce =

| tradename = Miripla

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_AU_comment =

| pregnancy_category=

| routes_of_administration =

| ATCvet =

| ATC_prefix =

| ATC_suffix =

| legal_AU =

| legal_AU_comment =

| legal_BR =

| legal_BR_comment =

| legal_CA =

| legal_CA_comment =

| legal_DE =

| legal_DE_comment =

| legal_NZ =

| legal_NZ_comment =

| legal_UK =

| legal_UK_comment =

| legal_US =

| legal_US_comment =

| legal_EU =

| legal_EU_comment =

| legal_UN =

| legal_UN_comment =

| legal_status = Rx in Japan

| bioavailability =

| protein_bound =

| metabolism =

| metabolites =

| onset =

| elimination_half-life =

| duration_of_action=

| excretion =

| CAS_number = 141977-79-9

| PubChem = 9832045

| DrugBank =

| UNII = 780F0P8N4I

| ChemSpiderID = 8007775

| KEGG = D06294

| IUPAC_name = Cyclohexane-(1R,2R)-diamineplatinum(II) dimyristate

| C=34|H=68|N=2|O=4|Pt=1

| smiles = CCCCCCCCCCCCCC(=O)[O-].CCCCCCCCCCCCCC(=O)[O-].C1CC[C@]([H])([C@@]([H])(C1)N)N.[Pt+2]

| StdInChIKey = BGIHRZPJIYJKAZ-BLUNCNMSSA-L

| StdInChI = 1S/2C14H28O2.C6H14N2.Pt/c2*1-2-3-4-5-6-7-8-9-10-11-12-13-14(15)16;7-5-3-1-2-4-6(5)8;/h2*2-13H2,1H3,(H,15,16);5-6H,1-4,7-8H2;/q;;;+2/p-2/t;;5-,6-;/m..1./s1

}}

Miriplatin (INN; trade name Miripla) is a drug used to treat hepatocellular carcinoma (HCC). It is a lipophilic platinum complex that is used in transcatheter arterial chemoembolization (TACE).{{cite web | url = https://drugs.ncats.io/substance/780F0P8N4I | title = Miriplatin | work = Inxight Drugs | publisher = National Center for Advancing Translational Sciences, National Institutes of Health }}{{cite journal | vauthors = Ikeda M, Kudo M, Aikata H, Nagamatsu H, Ishii H, Yokosuka O, Torimura T, Morimoto M, Ikeda K, Kumada H, Sato T, Kawai I, Yamashita T, Horio H, Okusaka T | display-authors = 6 | title = Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial | journal = Journal of Gastroenterology | volume = 53 | issue = 2 | pages = 281–290 | date = February 2018 | pmid = 28766016 | pmc = 5846877 | doi = 10.1007/s00535-017-1374-6 | author16 = Miriplatin TACE Study Group }} Miriplatin was approved by Japan's Pharmaceuticals and Medical Devices Agency in 2009.